Johnny Ludvigsson1, David Cuthbertson2, Dorothy J Becker3, Olga Kordonouri4, Bärbel Aschemeier4, Daniele Pacaud5, Cheril Clarson6,7, Jeffrey P Krischer2, Mikael Knip8,9,10,11. 1. Crown Princess Victoria Children's Hospital and Div of Pediatrics, Dept of Biomedical and Clinical Sciences, Linköping university, Linköping, Sweden. 2. Health Informatics Institute, University of South Florida, Tampa, Florida, USA. 3. Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA. 4. Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany. 5. Department of Pediatrics, Alberta Children's Hospital, Calgary, Alberta, USA. 6. Department of Paediatrics, University of Western Ontario, London, ON, Canada. 7. Lawson Health Research Institute, London, ON, Canada. 8. Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 9. Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 10. Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland. 11. Folkhälsan Research Center, Helsinki, Finland.
Abstract
OBJECTIVE: The β-cell stress hypothesis suggests that increased insulin demand contributes to the development of type 1 diabetes. In the TRIGR trial we set out to assess the profile of plasma glucose and HbA1c before the diagnosis of clinical diabetes compared to nondiabetic children. RESEARCH DESIGN AND METHODS: A cohort of children (N = 2159) with an affected first-degree relative and increased HLA risk were recruited 2002-2007 and followed until 2017. To study the relationship between plasma glucose/HbA1c and the development of autoantibodies or clinical disease Kaplan-Meir curves were developed. Mixed models were constructed for plasma glucose and HbA1c separately. RESULTS: A family history of type 2 diabetes was related to an increase in plasma glucose (p < 0.001). An increase in glucose from the previous sample predicted clinical diabetes (p < 0.001) but not autoantibodies. An increase of HbA1c of 20% or 30% from the previous sample predicted the development of any autoantibody (p < 0.003 resp <0.001) and the development of diabetes (p < 0.002 resp <0.001. Participants without autoantibodies had lower HbA1c (mean 5.18%, STD 0.24; mean 33.08 mmol/mol, STD 2.85) than those who progressed to clinical disease (5.31%, 0.42; 34.46 mmol/mol, 4.68; p < 0.001) but higher than those who developed any autoantibody (5.10%, 0.30; 32.21 mmol/mol, 3.49; p < 0.001), or multiple autoantibodies (5.11%, 0.35; 32.26 mmol/mol, 3.92; p < 0.003). CONCLUSIONS: A pronounced increase in plasma glucose and HbA1c precedes development of clinical diabetes, while the association between plasma glucose or HbA1c and development of autoantibodies is complex. Increased insulin demand may contribute to development of type 1 diabetes.
OBJECTIVE: The β-cell stress hypothesis suggests that increased insulin demand contributes to the development of type 1 diabetes. In the TRIGR trial we set out to assess the profile of plasma glucose and HbA1c before the diagnosis of clinical diabetes compared to nondiabetic children. RESEARCH DESIGN AND METHODS: A cohort of children (N = 2159) with an affected first-degree relative and increased HLA risk were recruited 2002-2007 and followed until 2017. To study the relationship between plasma glucose/HbA1c and the development of autoantibodies or clinical disease Kaplan-Meir curves were developed. Mixed models were constructed for plasma glucose and HbA1c separately. RESULTS: A family history of type 2 diabetes was related to an increase in plasma glucose (p < 0.001). An increase in glucose from the previous sample predicted clinical diabetes (p < 0.001) but not autoantibodies. An increase of HbA1c of 20% or 30% from the previous sample predicted the development of any autoantibody (p < 0.003 resp <0.001) and the development of diabetes (p < 0.002 resp <0.001. Participants without autoantibodies had lower HbA1c (mean 5.18%, STD 0.24; mean 33.08 mmol/mol, STD 2.85) than those who progressed to clinical disease (5.31%, 0.42; 34.46 mmol/mol, 4.68; p < 0.001) but higher than those who developed any autoantibody (5.10%, 0.30; 32.21 mmol/mol, 3.49; p < 0.001), or multiple autoantibodies (5.11%, 0.35; 32.26 mmol/mol, 3.92; p < 0.003). CONCLUSIONS: A pronounced increase in plasma glucose and HbA1c precedes development of clinical diabetes, while the association between plasma glucose or HbA1c and development of autoantibodies is complex. Increased insulin demand may contribute to development of type 1 diabetes.
Authors: G M Thernlund; G Dahlquist; K Hansson; S A Ivarsson; J Ludvigsson; S Sjöblad; B Hägglöf Journal: Diabetes Care Date: 1995-10 Impact factor: 19.112
Authors: Mikael Knip; Hans K Åkerblom; Eva Al Taji; Dorothy Becker; Jan Bruining; Luis Castano; Thomas Danne; Carine de Beaufort; Hans-Michael Dosch; John Dupre; William D Fraser; Neville Howard; Jorma Ilonen; Daniel Konrad; Olga Kordonouri; Jeffrey P Krischer; Margaret L Lawson; Johnny Ludvigsson; Laszlo Madacsy; Jeffrey L Mahon; Anne Ormisson; Jerry P Palmer; Paolo Pozzilli; Erkki Savilahti; Manuel Serrano-Rios; Marco Songini; Shayne Taback; Outi Vaarala; Neil H White; Suvi M Virtanen; Renata Wasikowa Journal: JAMA Date: 2018-01-02 Impact factor: 56.272
Authors: A Lauria; A Barker; N Schloot; N Hosszufalusi; J Ludvigsson; C Mathieu; D Mauricio; M Nordwall; B Van der Schueren; T Mandrup-Poulsen; W A Scherbaum; I Weets; F K Gorus; N Wareham; R D Leslie; P Pozzilli Journal: Eur J Endocrinol Date: 2014-11-06 Impact factor: 6.664
Authors: Kendra Vehik; David Cuthbertson; David Boulware; Craig A Beam; Henry Rodriguez; Laurent Legault; Mila Hyytinen; Marian J Rewers; Desmond A Schatz; Jeffrey P Krischer Journal: Diabetes Care Date: 2012-06-14 Impact factor: 17.152
Authors: Katharina Warncke; Andreas Weiss; Peter Achenbach; Thekla von dem Berge; Reinhard Berner; Kristina Casteels; Lidia Groele; Konstantinos Hatzikotoulas; Angela Hommel; Olga Kordonouri; Helena Elding Larsson; Markus Lundgren; Benjamin A Marcus; Matthew D Snape; Agnieszka Szypowska; John A Todd; Ezio Bonifacio; Anette-G Ziegler Journal: J Clin Invest Date: 2022-10-17 Impact factor: 19.456